Vertex Reports 9% Revenue Growth in 2025, Eyes Expansion in CF and Beyond
Event summary
- Vertex reported $12.0 billion in total revenue for 2025, up 9% from 2024, driven by cystic fibrosis (CF) therapies and early contributions from CASGEVY and JOURNAVX.
- Fourth-quarter 2025 revenue increased 10% year-over-year to $3.19 billion, with U.S. revenue up 12% and international revenue up 5%.
- Vertex provided 2026 revenue guidance of $12.95 billion to $13.1 billion, expecting continued growth in CF and $500 million or more from non-CF products.
- GAAP net income for 2025 was $4.0 billion, compared to a GAAP net loss of $536 million in 2024, reflecting increased product revenue and lower acquisition-related expenses.
- Vertex's cash position grew to $12.3 billion by the end of 2025, up from $11.2 billion at the end of 2024.
The big picture
Vertex's 2025 financial results highlight its strong position in the cystic fibrosis market and its successful diversification into other disease areas. The company's strategic focus on expanding its CF franchise, commercializing CASGEVY and JOURNAVX, and advancing its pipeline positions it well for continued growth in 2026. The biotechnology sector's emphasis on innovative therapies and commercial expansion aligns with Vertex's strategic direction, making it a key player in the industry.
What we're watching
- CF Franchise Growth
- Vertex's ability to sustain growth in its cystic fibrosis franchise will depend on the successful expansion of ALYFTREK into younger age groups and new geographies.
- Non-CF Product Revenue
- The company's goal of achieving $500 million or more in non-CF product revenue in 2026 hinges on the continued commercial success of CASGEVY and JOURNAVX.
- Pipeline Advancement
- The progress of Vertex's pipeline, including povetacicept for IgAN and other B cell-mediated diseases, will be critical in maintaining long-term growth.
Related topics